PE20180497A1 - Analogos de amilina - Google Patents
Analogos de amilinaInfo
- Publication number
- PE20180497A1 PE20180497A1 PE2017001497A PE2017001497A PE20180497A1 PE 20180497 A1 PE20180497 A1 PE 20180497A1 PE 2017001497 A PE2017001497 A PE 2017001497A PE 2017001497 A PE2017001497 A PE 2017001497A PE 20180497 A1 PE20180497 A1 PE 20180497A1
- Authority
- PE
- Peru
- Prior art keywords
- gly
- lsstnvgsnt
- lle
- apr
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
SE REFIERE A ANALOGOS DE AMILINA DE FORMULA R1-Z-R2, EN DONDE R1 ES H, ACILO C1-4, BENZOILO, ENTRE OTROS; R2 ES OH O NHR3, DONDE R3 ES H O ALQUILO C1-3; Z ES UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE: RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP; RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-lle(Me)-LSSTNVGSNT-Apr; y RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-lle(Me)-LSSTNVGSNT-Apr. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE OBESIDAD, DIABETES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15159737 | 2015-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180497A1 true PE20180497A1 (es) | 2018-03-09 |
Family
ID=52779493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017001497A PE20180497A1 (es) | 2015-03-18 | 2016-03-17 | Analogos de amilina |
Country Status (19)
Country | Link |
---|---|
US (2) | US10766939B2 (es) |
EP (1) | EP3271381B1 (es) |
JP (1) | JP6769984B2 (es) |
KR (1) | KR20170126504A (es) |
CN (1) | CN107567459B (es) |
AR (1) | AR103954A1 (es) |
AU (1) | AU2016232218B2 (es) |
BR (1) | BR112017019378A2 (es) |
CA (1) | CA2979950A1 (es) |
CL (1) | CL2017002256A1 (es) |
CO (1) | CO2017008870A2 (es) |
EA (1) | EA035791B1 (es) |
IL (1) | IL253924A0 (es) |
MX (1) | MX2017011182A (es) |
PE (1) | PE20180497A1 (es) |
PH (1) | PH12017501674A1 (es) |
SG (1) | SG11201707286UA (es) |
TW (1) | TW201706294A (es) |
WO (1) | WO2016146739A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017011182A (es) | 2015-03-18 | 2018-06-06 | Zealand Pharma As | Analogos de amilina. |
US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
WO2020077129A1 (en) | 2018-10-11 | 2020-04-16 | Intarcia Therapeutics, Inc. | Human amylin analog polypeptides and methods of use |
CN114641303A (zh) | 2019-11-11 | 2022-06-17 | 勃林格殷格翰国际有限公司 | Npy2受体激动剂 |
AU2021260870A1 (en) * | 2020-04-20 | 2022-12-08 | I2O Therapeutics, Inc. | Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics |
EP4192853A1 (en) | 2020-08-07 | 2023-06-14 | Boehringer Ingelheim International GmbH | Soluble npy2 receptor agonists |
BR112023002525A2 (pt) | 2020-09-24 | 2023-04-04 | Gubra Aps | Análogos de ham15-52 e composição farmacêutica |
WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
EP4129324A1 (en) | 2021-08-02 | 2023-02-08 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
CN113893349B (zh) * | 2021-12-13 | 2022-07-22 | 北京大学第三医院(北京大学第三临床医学院) | 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途 |
WO2023227133A1 (zh) * | 2022-05-27 | 2023-11-30 | 杭州先为达生物科技股份有限公司 | 人胰淀素类似物、其衍生物及用途 |
WO2023232781A1 (en) * | 2022-05-30 | 2023-12-07 | Zealand Pharma A/S | Liquid formulations of amylin analogues |
WO2024022465A1 (zh) * | 2022-07-29 | 2024-02-01 | 杭州九源基因工程有限公司 | 一种人胰淀素多肽衍生物及其用途 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175146A (en) | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
DK0567626T3 (da) | 1991-11-19 | 2001-12-17 | Amylin Pharmaceuticals Inc | Amylin-agonist-peptider og anvendelse deraf |
RU2177331C2 (ru) | 1993-09-07 | 2001-12-27 | Амилин Фармасьютикалз, Инк. | Способы регулирования моторики желудочно-кишечного тракта |
PL192359B1 (pl) | 1996-08-30 | 2006-10-31 | Novo Nordisk As | Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37) |
WO1998011125A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
US5677279A (en) | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
US7101853B2 (en) | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
US7910548B2 (en) | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
WO1999034764A2 (en) | 1998-01-09 | 1999-07-15 | Amylin Pharmaceuticals, Inc. | Amylin agonist pharmaceutical compositions containing insulin |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
RU2001128068A (ru) | 1999-03-17 | 2004-02-20 | Ново Нордиск А/С (DK) | Способ ацилирования пептидов и новые ацилирующие агенты |
WO2005000222A2 (en) | 2003-05-30 | 2005-01-06 | Amylin Pharmaceuticals, Inc. | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
US8114958B2 (en) | 2004-02-11 | 2012-02-14 | Amylin Pharmaceuticals, Inc. | Amylin family peptides |
EP1718665B1 (en) | 2004-02-11 | 2013-04-10 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
DE102004051014A1 (de) | 2004-10-20 | 2006-04-27 | Rwth Aachen | Chemisch modifizierte Peptidanaloga |
EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
US8486890B2 (en) | 2006-03-15 | 2013-07-16 | Novo Nordisk A/S | Amylin derivatives |
KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
WO2010046357A1 (en) | 2008-10-21 | 2010-04-29 | Novo Nordisk A/S | Amylin derivatives |
MA32970B1 (fr) | 2008-12-15 | 2012-01-02 | Zealand Pharma As | Analogues du glucagon |
CN102292347A (zh) | 2008-12-15 | 2011-12-21 | 西兰制药公司 | 胰高血糖素类似物 |
WO2010070255A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
US8748375B2 (en) | 2009-03-17 | 2014-06-10 | Amylin Pharmaceuticals, Llc | Methods for affecting body composition using amylin agonists |
ME02220B (me) | 2009-07-13 | 2016-02-20 | Zealand Pharma As | Analozi acilovanog glukagona |
WO2011064282A1 (en) | 2009-11-25 | 2011-06-03 | Novo Nordisk A/S | Method for making polypeptides |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
BR112012033225A2 (pt) | 2010-06-24 | 2017-06-20 | Zealand Pharma As | análogos do glucagon |
US8575090B2 (en) | 2011-06-10 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
BR112014015681A2 (pt) | 2011-12-23 | 2019-09-24 | Boehringer Ingelheim Int | análogos de glucagon |
US8575091B1 (en) | 2012-04-19 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
CN104395338B (zh) * | 2012-04-19 | 2019-05-10 | 诺和诺德股份有限公司 | 人胰岛淀粉样多肽类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
JP2016208556A (ja) * | 2013-10-03 | 2016-12-08 | 三菱電機株式会社 | デマンド予測装置及びデマンド予測方法 |
CA2947587C (en) | 2014-05-02 | 2022-10-18 | The Research Foundation For The State University Of New York | Islet amyloid polypeptides with improved solubility |
EP3189071B1 (en) | 2014-09-04 | 2021-07-28 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
MX2017011182A (es) | 2015-03-18 | 2018-06-06 | Zealand Pharma As | Analogos de amilina. |
US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
-
2016
- 2016-03-17 MX MX2017011182A patent/MX2017011182A/es unknown
- 2016-03-17 JP JP2017548895A patent/JP6769984B2/ja active Active
- 2016-03-17 WO PCT/EP2016/055793 patent/WO2016146739A1/en active Application Filing
- 2016-03-17 BR BR112017019378-7A patent/BR112017019378A2/pt not_active IP Right Cessation
- 2016-03-17 AU AU2016232218A patent/AU2016232218B2/en not_active Ceased
- 2016-03-17 CA CA2979950A patent/CA2979950A1/en not_active Abandoned
- 2016-03-17 PE PE2017001497A patent/PE20180497A1/es unknown
- 2016-03-17 CN CN201680015858.2A patent/CN107567459B/zh active Active
- 2016-03-17 EP EP16713772.8A patent/EP3271381B1/en active Active
- 2016-03-17 AR ARP160100708A patent/AR103954A1/es unknown
- 2016-03-17 SG SG11201707286UA patent/SG11201707286UA/en unknown
- 2016-03-17 KR KR1020177029942A patent/KR20170126504A/ko unknown
- 2016-03-17 EA EA201791617A patent/EA035791B1/ru unknown
- 2016-03-18 TW TW105108579A patent/TW201706294A/zh unknown
- 2016-03-18 US US15/074,526 patent/US10766939B2/en active Active
-
2017
- 2017-08-09 IL IL253924A patent/IL253924A0/en unknown
- 2017-08-30 CO CONC2017/0008870A patent/CO2017008870A2/es unknown
- 2017-09-06 CL CL2017002256A patent/CL2017002256A1/es unknown
- 2017-09-13 PH PH12017501674A patent/PH12017501674A1/en unknown
-
2020
- 2020-08-06 US US16/986,790 patent/US20210115104A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3271381B1 (en) | 2021-09-08 |
CO2017008870A2 (es) | 2017-11-10 |
WO2016146739A1 (en) | 2016-09-22 |
EA035791B1 (ru) | 2020-08-11 |
KR20170126504A (ko) | 2017-11-17 |
BR112017019378A2 (pt) | 2019-02-19 |
CL2017002256A1 (es) | 2018-04-02 |
JP2018510871A (ja) | 2018-04-19 |
PH12017501674A1 (en) | 2018-03-12 |
MX2017011182A (es) | 2018-06-06 |
IL253924A0 (en) | 2017-10-31 |
TW201706294A (zh) | 2017-02-16 |
JP6769984B2 (ja) | 2020-10-14 |
US20160272693A1 (en) | 2016-09-22 |
US10766939B2 (en) | 2020-09-08 |
CN107567459B (zh) | 2021-09-24 |
CA2979950A1 (en) | 2016-09-22 |
EA201791617A1 (ru) | 2018-02-28 |
EP3271381A1 (en) | 2018-01-24 |
AU2016232218A1 (en) | 2017-09-21 |
US20210115104A1 (en) | 2021-04-22 |
AU2016232218B2 (en) | 2020-09-10 |
AR103954A1 (es) | 2017-06-14 |
CN107567459A (zh) | 2018-01-09 |
SG11201707286UA (en) | 2017-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180497A1 (es) | Analogos de amilina | |
PE20171322A1 (es) | Dinucleotidos ciclicos utiles para el tratamiento del cancer entre otros | |
PE20150627A1 (es) | Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso | |
CL2016000873A1 (es) | Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento. | |
BR112018006920A2 (pt) | agonistas dos receptores de glucagon | |
PE20142452A1 (es) | AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2 | |
BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
BR112018075259A2 (pt) | composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0 | |
EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
PE20130281A1 (es) | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae | |
CL2018000688A1 (es) | Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias | |
PE20142098A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
AR094966A1 (es) | Composiciones farmacéuticas para el tratamiento de infecciones hcv | |
AR065806A1 (es) | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. | |
MX2016002368A (es) | Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1). | |
PE20150224A1 (es) | Inhibidores del nampt | |
ECSP18061667A (es) | Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza | |
EA201400827A1 (ru) | Материалы и способы лечения диареи | |
EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
EA201700504A1 (ru) | 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение | |
PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
EA201790570A1 (ru) | Модуляторы р2х7 | |
PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
EA201590364A1 (ru) | Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда |